
Annual report 2024
added 12-27-2025
Evogene Ltd. Net Debt 2011-2025 | EVGN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Evogene Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -3.44 M | -3.24 M | -10.2 M | -5.21 M | -95.5 M | -24.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.24 M | -95.5 M | -23.6 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.87 | 11.68 % | $ 477 M | ||
|
Aclaris Therapeutics
ACRS
|
-22 M | $ 3.0 | -0.99 % | $ 232 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.1 | -0.64 % | $ 7.46 B | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 1.1 | -3.51 % | $ 6 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 211.15 | 1.04 % | $ 5 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
BioVie
BIVI
|
-17.2 M | $ 1.22 | 0.83 % | $ 1.8 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 0.17 | -18.84 % | $ 370 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 95.17 | 0.69 % | $ 27.2 B | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 12.12 | -1.86 % | $ 798 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 26.86 | -0.96 % | $ 1.3 B | ||
|
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 9.53 | -0.21 % | $ 140 M | ||
|
Certara
CERT
|
119 M | $ 8.85 | -0.45 % | $ 1.42 B | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
Cellectis S.A.
CLLS
|
-206 M | $ 4.95 | 4.2 % | $ 116 M | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Axon Enterprise
AXON
|
-404 M | $ 583.1 | -0.13 % | $ 44.2 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.55 | 4.08 % | $ 16 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | $ 92.68 | -0.24 % | $ 96.9 B | ||
|
ChromaDex Corporation
CDXC
|
-26.5 M | - | -0.88 % | $ 598 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 9.25 | 1.82 % | $ 1.49 B | ||
|
Celldex Therapeutics
CLDX
|
-24.5 M | $ 25.93 | -1.8 % | $ 1.67 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
455 M | $ 11.43 | 2.65 % | $ 739 M |